Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up

Overview of attention for article published in Annals of Hematology, January 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 29 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 16 publications that cite this research output.

16

The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.

Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia

Article in Expert Review of Hematology (April 2024)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens

Article in Hematology (April 2024)

Chemotherapy with the use of next‐generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

Article in Cancer (March 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.